Tesfaye Solomon, Chaturvedi Nish, Eaton Simon E M, Ward John D, Manes Christos, Ionescu-Tirgoviste Constantin, Witte Daniel R, Fuller John H
Diabetes Research Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom.
N Engl J Med. 2005 Jan 27;352(4):341-50. doi: 10.1056/NEJMoa032782.
Other than glycemic control, there are no treatments for diabetic neuropathy. Thus, identifying potentially modifiable risk factors for neuropathy is crucial. We studied risk factors for the development of distal symmetric neuropathy in 1172 patients with type 1 diabetes mellitus from 31 centers participating in the European Diabetes (EURODIAB) Prospective Complications Study.
Neuropathy was assessed at baseline (1989 to 1991) and at follow-up (1997 to 1999), with a mean (+/-SD) follow-up of 7.3+/-0.6 years. A standardized protocol included clinical evaluation, quantitative sensory testing, and autonomic-function tests. Serum lipids and lipoproteins, glycosylated hemoglobin, and the urinary albumin excretion rate were measured in a central laboratory.
At follow-up, neuropathy had developed in 276 of 1172 patients without neuropathy at baseline (23.5 percent). The cumulative incidence of neuropathy was related to the glycosylated hemoglobin value and the duration of diabetes. After adjustment for these factors, we found that higher levels of total and low-density lipoprotein cholesterol and triglycerides, a higher body-mass index, higher von Willebrand factor levels and urinary albumin excretion rate, hypertension, and smoking were all significantly associated with the cumulative incidence of neuropathy. After adjustment for other risk factors and diabetic complications, we found that duration of diabetes, current glycosylated hemoglobin value, change in glycosylated hemoglobin value during the follow-up period, body-mass index, and smoking remained independently associated with the incidence of neuropathy. Cardiovascular disease at baseline was associated with double the risk of neuropathy, independent of cardiovascular risk factors.
This prospective study indicates that, apart from glycemic control, the incidence of neuropathy is associated with potentially modifiable cardiovascular risk factors, including a raised triglyceride level, body-mass index, smoking, and hypertension.
除血糖控制外,尚无治疗糖尿病神经病变的方法。因此,识别神经病变潜在的可改变风险因素至关重要。我们在参与欧洲糖尿病(EURODIAB)前瞻性并发症研究的31个中心的1172例1型糖尿病患者中,研究了远端对称性神经病变发生的风险因素。
在基线期(1989年至1991年)和随访期(1997年至1999年)评估神经病变,平均(±标准差)随访7.3±0.6年。标准化方案包括临床评估、定量感觉测试和自主神经功能测试。血清脂质和脂蛋白、糖化血红蛋白以及尿白蛋白排泄率在中心实验室测量。
随访时,基线时无神经病变的1172例患者中有276例发生了神经病变(23.5%)。神经病变的累积发生率与糖化血红蛋白值和糖尿病病程有关。在对这些因素进行调整后,我们发现总胆固醇、低密度脂蛋白胆固醇和甘油三酯水平较高、体重指数较高、血管性血友病因子水平和尿白蛋白排泄率较高、高血压和吸烟均与神经病变的累积发生率显著相关。在对其他风险因素和糖尿病并发症进行调整后,我们发现糖尿病病程、当前糖化血红蛋白值、随访期间糖化血红蛋白值的变化、体重指数和吸烟仍与神经病变的发生率独立相关。基线时的心血管疾病与神经病变风险增加一倍相关,与心血管风险因素无关。
这项前瞻性研究表明,除血糖控制外,神经病变的发生率与潜在的可改变心血管风险因素有关,包括甘油三酯水平升高、体重指数、吸烟和高血压。